Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost adults with a BMI of 30 or above — or a BMI of 27 or above alongside a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol — can be considered for Mounjaro. Whether you're actually suitable is a clinical decision, not a self-assessment. Mounjaro (tirzepatide) is a prescription-only medicine, which means a GPhC-registered prescriber must review your health before any treatment begins. The steps below explain how that process works in practice and what clinicians actually look at when deciding if you can go on Mounjaro.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The starting point is your BMI. The UK licence for Mounjaro covers adults with a BMI of 30 or above, or 27 or above when at least one weight-related condition is present. Conditions that count include type 2 diabetes, prediabetes, hypertension, high cholesterol, obstructive sleep apnoea and certain others. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, UK guidance applies thresholds that are 2.5 kg/m² lower, so the numbers shift accordingly.
That's the licence. It sets a floor, not an approval. A prescriber still needs to be satisfied that Mounjaro is appropriate for you specifically. Some people who technically meet the BMI threshold have medical histories (a personal or family history of medullary thyroid carcinoma, certain gastrointestinal conditions, or a history of pancreatitis) that would prompt more caution or rule treatment out entirely. The full overview of Mounjaro covers what those conversations with a clinician typically involve.
The NHS BMI calculator at nhs.uk gives you a quick reference figure if you're not sure where you stand before filling in a consultation form.
Once you decide to go ahead, the consultation is the core of the process. At nume, that means answering a structured set of health questions covering your BMI, weight history, any existing diagnoses, medicines you're currently taking and your goals. Your identity is confirmed with photo ID, and your weight is verified on a live video call, not self-reported and taken on trust.
A GPhC-registered Independent Prescriber then reads through your responses the same day. A real clinician reviews your answers, not a piece of software working through a ruleset. If everything is clinically appropriate, a prescription is issued and your treatment is dispatched. Our clinical team oversees this at every stage.
One practical detail: if you order before 12 pm on a weekday, approved treatment leaves the same day and arrives with DPD the next working day, in plain unbranded packaging. The pen itself is compact and pre-filled, each KwikPen holds four weekly doses.
Going on Mounjaro is not a single transaction. It is an ongoing clinical relationship. Treatment begins at 2.5 mg (a starting dose designed to help your system settle before any titration) and moves forward under prescriber guidance, typically in four-week steps. Your prescriber leads that; you don't self-adjust.
Before each repeat supply, a clinical review takes place. That is standard practice and a patient-safety requirement, not an inconvenience. If you're considering how long a course actually runs, the pages on short-term use and three-month courses set out what the evidence says about duration. Cost context is covered plainly on the Mounjaro prices page.
Side effects are mostly gastrointestinal (nausea, loose stools, constipation, indigestion) and tend to peak after a dose change before settling. Severe, persistent stomach pain that radiates to the back warrants urgent medical attention, as the MHRA has highlighted in its guidance on GLP-1 medicines. You can report any suspected side effects through the MHRA's Yellow Card scheme. Women taking oral contraceptives should know that absorption of the pill may be reduced during the first four weeks of Mounjaro and for four weeks after each dose increase; a non-oral contraceptive method is advisable during those windows.
If you're still weighing things up (whether Mounjaro is right for you at all is a genuine question worth sitting with) that's what the consultation process is designed to accommodate. A prescriber is not there to rubber-stamp a request; they're there to help you reach a considered decision. Questions our prescribers hear regularly: what happens if I stop, can I restart after a break (covered on the returning to Mounjaro page), and what does treatment actually feel like day to day.
If you'd like to explore what weight-loss treatment options look like more broadly before committing, that's a sensible starting point too. When you're ready to find out whether you personally can go on Mounjaro, the next step is a free clinical consultation with our prescribers at the treatments page. No obligation, no hidden fees, just a proper clinical assessment.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.